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second  Commission  report  on  the functioning  of the Committee  for Proprietary 
Medicinal  Products  and  i·ts  impact  on  the development  of  intra-Community  trade 
(1979) 
Council  Directive 75/319/EEC  relating to proprietary medicinal  products 
(OJ  L 147  of 9  June  1979)  provides,  in  Arti~te 15(1), that  ~the Commission 
shall  report  to the Council  annually on  the operation of  the procedure  lai~ 
down  in this Chapter  (Committee  for  Proprietary Medicinal.  ·Products)· and  its 
effects on  the' development  of  intra-Community trade". 
This  report  covers the year  1979. 
I.  THE  FUNCTIONING  OF  THE  COMMITTEE  FOR  PROPRIETARY  MEDI~INAL-PRODUCTS 
_(a)  Committee 
The  terms  of office of the members  were  renewed  as  from  1  December  1979. 
The  membership  of_the Committee  was  not  changed  as  regards the full 
members. 
Dr.  JONES,  Principal Medical  Officer, Medicines  Division,  was  appointed 
an  alternate member  for the  United  Kingdom. 
It was  resolved that  the Chairman  and  Vice-Chairmen  of the Committee 
would  remain  in-their office (cf.  Annex  I). 
Cb>  Groups  of  experts 
The  membership  of the groups  of experts  ~as varied according  to the  items 
on  the agenda.  A list of the participants in these groups  is given  in 
Annex  II. 
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The  Committee  met  ·six  times,  on  the  following  dates:  20  February  1979, 
13  and  14  March,  19  and  20  April,  7  and  8  June,  11  and  12.September, 
14  November. 
~ 
The  "Safety of Drugs"  panel  met  three times,  i.e., on  16  and  17  January_  ,.._ 
1979,  3  and  4  April  and  3  and  4.December. 
The  "Efficacy of  Dr·ugs"  panel  also met ·three times,  i.e.,on 13  and  14 
February  'i979,  3  and  4  April  and  3  and  4  December. 
The 
11Medicinal  Products  of  Plant Origin" panel  met  on  12  March  1979. 
3.1  Opinions  on  the basis of  Article 11  of  Directive 75/319/EEC 
Until 3'  December  1979  two  opinions  were. delivered by: tha.committee. 
Fu~thermore, two  new  appl.i cations for marketing  authorization were  forwar-
ded,  pursuant to Arti.cle 9  of  Directive 75/319/EEC.  The  procedure  in the 
case·•:>f  t~ese .:two  new  applications  had  not  been  completed  by  the end of 
the period  covered  by  this report. 
In  spite of this very  limited experience,  the following  facts  emerged: 
not  all manufacturers presented the particulars in  conformity with 
the plan adopted  by  the Committee  for Proprietary Medicinal  Products 
and  reproduced  in the booklet  published by  the Commission  of the 
European  Communities  in 1978  under  the title "The  rules governing 
medicamet'lts  in the European  Community",  page  57 et  seq.  This  caused 
·loss of  time at  the  Level  of  both  national  and  Community  examination;· 
it is difficult,  in the absence of ~Uidetines prepared  by  the panels 
of experts of the  Committe~, to achieve  compl~te  harmoni~ation of 
the therapeutic  indications,  contra-indications, warnings  and  side-
effects,  since different  national  attitudes have  been  adopted 
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for  v1rious products  of  a  a1m1lar  n1ture  and  that it would  therefore 
be  difficult to justify at national  level  an  abrupt  c~ange of doctrine 
for "a  particular case;-
-supervision of_the stability period brought  to  light divergent atti-
tudes:  certain authorities accept  accelerated studies, others only 
accept  real-time trials; 
- certain authorities  contacted the  applicant  during  the 120  days  of 
examination  and  thus  have  additional ·information-which the other 
authorities  do  not  possess; 
the time-limits  laid down  in Articles 10  and  11  of the abovementioned 
Directive are  very  short,  even  if it has  been  possible to  comply  with 
them  in this case; 
- the time for  sending  files 9Y  post  to all the Member  States specified 
has  never  been  Less  than one  month. 
3.2 Opinion  on  the basis of  Article 12  of  Directive 75/319/EEC 
On  the basis of the abovementioned  Article 12,  the Committee  was  asked 
for  an  opinion concerning  clofibrate. 
All  the delegations,  exc~pt one,.stated that clofibrate would  remain  on 
their  respective markets  subject  to  limitation of  the  indications, the 
formulation of revised  warnings  and  contra-indications and  special 
information for the medical  profession. 
Subsequently,  all the national  authorities adopted  an  attitude identical 
to that  reported  above. 
3.3 Opinion  on  the basis of Article 14  of  Directive 75/319/EEC 
The  Committee  was  consulted on  and  duly  examined  the following  medicines 
for problems  of  interest to the  Community:  Alclofenac,  Ami~ophenazone 
and  derivatives,  Benperidol,  Biguanides  (Buformine,  Metformine, 
Phenformine),  Chloramphenicol,  Clioquinol, ·oinoprostone,  Furazolidone-, 
Hydrazinophtalazine,  Inosine, Methapyrilene,  Noramidopyrine,  Triazolam  • 
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The  three panels of experts set  up  in  accordance  with  Articte 13  of the 
Committee's  rules  of  procedure  continued their work. 
4.1  The  panel  on  "Safety of  Drugs",  chaired by  Dr  J.P.  GRIFFIN,  has  completed. 
the drafting, after consultation with  national  authorities and  private 
associations  and  examination of their  comments,  of the following 
guidelines: 
- single dose  toxicity studies; 
- repeated dose  toxicity studies; 
- reproduction studies; 
- carcinogenicity studies; 
- inhalation toxicity studies; 
- pharmacokinetics. 
A guidetine on  the  rutagenicity tests has  still to be  revised  in the 
light of the comments  ~eceived. 
4.2  The  panel  on  "Efficacy of  Drugs",  chaired by  Dr  M.N.G.  DUKES,  has 
comp~eted the drafting, after consultation with  national  authorities 
and  private associations  and  examination of their comments,  of  a 
guideline on  fixed  combinations  of  medicines.  After  a  final  revision, 
the  same  procedure  wilt  be  applied to the note on  anti-inflammatory 
preparations. 
The  following  guidelines are being  prepared or are at the planning .stage: 
- antiepileptics/anticonvulsants; 
- bioavialability; 
- cardiac glycosides; 
-human  pharmacokinetics; 
- antianginal  agents; 
-oral contraceptives .(tests); 
- oral  contracE:ptives  (information for  users>; 
- antihypertensive agents; 
- hypoglycemic  agents; 
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antiarrhythmic  agents; 
- medicines  used  over  a  long  period;-
- local  corticoids; 
-peripheral vasodilators; 
- antimicrobial  agents; 
- medicines  and  pregnancy; 
- diuretics; 
- contrast  media. 
4.3  The  panel  on  "Medicinal  Products  of  Plant  Origin",  chaired by 
Professor B.  SCHNIEDERS,  considered it advisable,  before proceeding 
further,  to  collect bibliographical data  on  the quality,  efficacy 
and  harmlessness  of plants and  preparations based on-plants. 
4.4 After  the adoption of these guidelines  by  the Committee  for  Proprietary_ 
\ 
Medicinal  Products,  it will  rest  with  the Commission  to give them  the 
appropriate  legal form. 
5.1  the Committee  has  amended  or clarified the notice to the manufacturers 
and  importers of proprietary medicinal  products published  in  OJ  N° 
C 302  of  15  December  1977,  with  regard to the following  three points: 
-the languages  in  which  certain parts of the file can  be  supplied; 
-the countries  which  request  that the file be  accompanied  by  samples 
of the proprietary product; 
- the fact  that the national  registration fees  remain  applicable  as  laid 
down  by  the national  laws. 
5.2  The  Committe~ expressed its opinion on  the desirability of  drawing  up 
a  Community  modet  of  a  data  sheet  which  would  be  used  to summarize  the 
marketing  authorization and  which  could  also be  used  for other purposes, 
e.g., medical  information.  It has  prepared a  list of the essential 
information to be.stated on  this sheet. 
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5.3 The  Committee  also assessed the situation with  regard to drug  monitoring 
and  considered that  there should  be  more  systematic mutual  information 
on  any  potential danger.  An  early-warning  system  has  been  introduced for 
this purpose. 
5.4 The  system  laid down  in  Article 33  ~f Directive 75/319/EEC  for notifying 
,decisions  adopted  by  the competent  authorities has  been  improved. 
A special treatment  has  been  instituted for marketing  authorizations 
concerning  new  substances,  salts or esters,  new  routes of  administration, 
new  combinations,  important  new  indications and  new  dosages  and  for 
refusals and  revocations of MAs,.  the prohibition.of supply and  with-
drawal  from  the market. 
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II.  DEVELOPMENT  OF  INTRA-COMMUNITY  TRADE 
The  data are  ta~en from  the Analytical  Tables-of  Foreign  Trade- NIMEXE 
1978  - published  QY  the Statistical Office of the European  Communities. 
The  statistics are given  in  European  units of  account  CEUA>. 
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2.  c)  Percentage  o'f  medicaments  packaged  for  retail sale in total  Community 
medicaments  imports 
In  1978  medicaments  packaged  for  retail sale accounted  for 64.5  % of 
medicaments  imported  by  the Community.  This  figure  is slightly lower 
compared  with  those for previous years,  which  were  marked  by  a·constant 
.  increase in the relevant  figure  since 1974  (66  X in 1977,  65  X in 1976; . 
64  X in 1975,  63  % in 1974>. 
If only intra-Community  imports  are considered, packaged  medicaments 
account  for 71.3 X of the total  intra-Community  imports of medicaments 
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7.  Comments 
It is, of  course,  unnecessary to assess the effects of the Committee's 
procedure on  the development  of  intra-Community trade,  in view  of the 
fact that it has  been  used  so little. 
• 
'  .. t-.r 
ANNEX  I 
COMITE  DES  SPECIALITES  PHARMACEUTIQUES 
COMMITTEE  FOR  PROPRIETARY  MEDICINAL  PRODUCTS 
President  I  Chairman: 
M.  Leon  ROBERT 
Vice~Presidents I  Deputy  Chairmen:· 
1. Prof.  Duilio POGGIOLINI 
2 •.  M.  Nicolaas BEL 
a>  Representants  I  Representatives: 
b>  Suppleants  I  Deputies: 
BELGIQUE 
a)  M.  Ben  HUYGHE 
b)  Mme.  Denise  TORFS-BRUOER 
OANMARK 
a)  Mr.  Steen  ANTv~SEN 
b)  Mr.  H~ns Otto  ANDERSEN 
18,  rue J.P.  Koenig 
Luxembourg 
Tel.:  260.76 
Direttore Generate del Servizio  Farma-· 
ceutico 
Ministero della Sanita 
Via  Civilta -Romane 
ROMA  EUR  '1  · 
Tel.:  59.58.63  I  59.58.24 
Telex  610453  MINSAN 
Chef  de  Division a la  Direction generale 
du  Marche  interieur et  des 
Affaires .industrielles 
Commission  des  Communautes  europeennes 
1049  Bruxelles,  rue de  La  Loi  200 
Tel.:  735.00.40 I  1891 
Inspecteur  General,  Inspection generale 
de  La  Pharmacie 
Minist~re de  la Sante  publique 
Cite  Administrative,  Quartier  V's~le 
1010 Bruxelles 
Tel.:  564.10.64 
Te le.K:  25.798 
Pharmacien-Inspecteur, 
Inspection generate de  la Pharmacie 
Ministere  de  la Sante publique 
Cite Administrative, Quartier Vesale 
1010  Bruxelles 
Tel.:  564.10.64 
Telex:  25.798 
Laboratoriechef 
Sundhedsstyrelsen,  Farmaceutiske  Labora-
torium 
Frederikssundsvej  378,  DK-2700  Br~nsh~j 
Tel.:  02-94.37.73 
Telex:  35333  (ANTONSEN)Canswer:  IPHARM  DK) 
Sekretariatschef, 
Sundhedsstyrelsen,  Farmaceutiske  Labor. 
Frederikssundsvej  387,  OK-2700-Br~nsh~j 
Tel.:  02-94.37.73 
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BUNO!SR!PUBLIK  D!UTSCHLANC 
a)  Prof.  Dr.  Bernhard  SCHNIEDERS  Leiter des  Instituts fur  Arzneimittel  des 
Bundesgesundheitsamtes 
b)  Prof.  Dr.  Gunter  ABmann 
FRANCE 
a)  M.  Jean WEBER 
b)  M.  Pierre GRECH 
IRELAND 
a)  Dr.  Alene  SCOTT 
b>  Prof.  Oliver  FitzGerald 
ITALIA 
a)  Prof.  Duilio POGGIOLINI 
b)  Dott~  Romano  CAPASSO 
o-1000 Berlin 30,  Stauffenbergstr.  13  ~ 
Tel.:  26.37.203 oder  204 
Telex:  183310 
Leiter der  Abteilung  "Pharmazeutische 
Fragen  der  Arzneimittelzulassung" des 
Instituts fur  Arzneimittel  des  Bundes-
gesundheitsamtes 
0-1000  Berlin 30, Stauffenbergstr.  13 
Ttlex  183310 
Oirecteur de  la Pharmacie  et du Medicament, 
Mini stere de  la  Sante  publ ique et  de  la 
securite sociale 
1, Place  Fontenoy,  75007  Paris 
Tel.:  567.55.44 
Ligne  directe:  306.59.47 
Telex:  ~50011  SANTSEC  F 
Pharmacien-Inspecteur de  la Sante  au  Service 
Central  de  la  Pharmacie et des Medicaments 
Ministe~re de  La  sante publique et de  La 
Securite sociale 
1, Plac1  Fontenoy,  75007  Paris 
Tel.:  5!67.55.44 
Medical  Director 
National  Drugs  Advisory  Board 
57  C Harcourt  Street 
Dublin  2 
Tel.:  68.10.98 
Telex:  4894  (Department  of Health> 
Chairman  of the National  Drugs  Advisory Soard 
57  C Harcourt  Street,  Dublin  2 
Tel.:  68.10.98 
Direttore Generate del  Servizio  Farmaeeutico 
Ministero della  San~ta 
Via  Civilta  Romane 
ROMA  EUR 
Tel.:  59.58.63  I  59.58.24 
Telex:  610453  M!NSAN 
Dirigente  Superiore  Chimico 
Ministero della San1ta 
Oirezione Generale  Servizio  Farmaeeutico 
Vi a  Ci v·i l t~  Romane 
ROMA  EUR 
Tel.:  59.58.63  I  59.58.24 ANNEX  II  - 1  -
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Dr.  J.P.  Griffin 
Senior Principal  Medical  Officer 
Medicines  Division 
D.H.S.S. 
Fins~ury Square  House 
33-37A  finsbury  Square 
London  EC2A  1PP 
Professor J.  Van  Noordwijk 
Rijks-Instituut  voor  de 
Volksgezondheid 
P.O.  Box  1 
3720  BA  Bilthoven 
Netherlands 
Professor Jens  s.  Schou 
Department  of  Pha~macology 
University of  Copenhagen 
20  Jutiane Maries  Vej 
DK-2100  Copenhagen  0 
Denmark 
Professor H.O.  Brede 
Paul-Ehrtich-Institut 
Paul-Ehrlich-Str.  42-44 
D-6000  Frankfurt/M. 
O.eutschland 
Dr.  P.  Grosdanoff 
Institut  fDr  Arzneimittel  des 
Buncesgesundheitsamtes 
Stauffenbergstr.  13 
o-1000  Berlin 30 
Deutschland 
Or.  w.  Christ 
·znstitut  fur  Arzneimittel  des 
Bundesgesundheitsamtes 
Stauffenbergstr.  13 
0-1000  Berlin 30 
Deutschland 
Professor R.  Bass 
Institut  fur  Arzneimittel  des 
Bundesgesundheitsamtes 
Stauffenbergstr.  13 
D-1000  Berlin 30 
Deutschland 
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Dr.  Morrell  Draper 
Department  of  Health  and  Social Security 
Medicines  Division 
Finsbury  Square  House 
33-37A  Finsbury  Square 
London  EC2A  1PP 
United  Kingdom 
Professor Giorgio  Segre 
Istituto di  Farmacologia 
Universita di  Siena 
Via  Banchi  de  Sotto 55 
53100  Siena 
Italy 
Professor c.  Harvengt 
Laboratoire de  Pharmacotherapie 
Universite  Catliolique de  Louvain 
Site de  Louvain  en  Woluwe 
·UCL  5349  Tour  Pasteur 
1200  Bruxelles 
Belgique 
Or.  M.  Conatty 
Medical  Research  Council  Laborator~es 
Tri ndty  College 
Dublin 
Ireland 
Prof.  G.  Olive 
I.N.S.E.R.M. 
101,  rue  de  Tolbiac 
F-75013  Paris 
France 
Professor G.  Stille 
Institut fur Arzneimittel des 
Bundesgesundheitsamtes 
Stauffenbergstr.  13 
D-1000  BP.rlin  30 
Deutschland 
Dr.  G.  Jones 
Principal  Medical  Officer 
Medicines  Division 
o.H.s.s. 
Finsbury  Square  House 
33-37A  Finsbury  Square 
london  EC2A  1PP 
United Kingdom 
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Luxembourg 
Tel.:  47.55.01 
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b)  Mlle.  Marie-Therese  STROMMENGER  Pharmacien  attache a l'Inspection des 
Pharmacies,  Ministere de  la Sante  publ  ique·, 
Boulevard  Joseph II, 28 
NEDERLAND 
a>  Dr.  C.A.  TEIJGELER 
b)  Dr.  M.N.G.  DUKES 
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a>  Dr.  J.P.  GRIFFIN 
b)  Dr.  G.  JONES 
CCE  I  CEC 
a)  M.  Nicolaas  BEL 
b)  M.  Pierre  DUPRAT 
I  ~ 
Luxembourg 
Tel.:  47.55.01 
Voorzitter,  College ter Beoordeling  van 
Geneesmiddelen 
Ministerie  van  Volksgezondheid 
Dr.  Reijersstraat  10,  Leidschendam. 
Tel.:  (070>  20.92.60 
Telex:  32362  oder  32347 
Plaatsverv.  Voorzitter,  College ter 
Beoordeling  van  Geneesmiddelen 
Ministerie van  Volksgezondheid 
Dr.  Reijersstraat 10, Leidschendam 
Tel.:  <070>  20.92.60 
Senior Principal  Medical  Officer 
Medic;nes  Division 
Department  of  Health  and  Social Security 
Finsbury  Square  House 
33-37A  Finsbury  Square,  London  EC2A  1PP 
Tel.:  (01>  638.60.20,  ext.  388 
Principal Medical  Officer 
Medicines  Division 
Department  of  Health  and  Social  Security 
Finsbury  Square  House 
33-37A  Finsbury  Square,  London  EC2A  1PP 
Tel.:  C01>  638.60.20,  ext.  385 
Chef  de  Division a la  ~irection generale 
du  Marche  interieur et des Affaires 
industrielles 
Commission  des  Communautes  europeennes 
1049  ~ Bruxelles,  rue  de  la Loi  200 
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Administrateur principal, 
Direction  g~nerale du  Marche  interieur et 
des  Affaires  industrielles 
Commission  des  Communautes  europeennes. 
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Tel.:  735.00.40 I  3524 
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Dr.  Enrico  GENAZZANI 
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esperimentale 
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Department- of  Health  and 
Medicines  Division 
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Central  Drug  Inspectorate 
Ministry of Public  Health  and 
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Leidschendam 
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Prof.  Oliver  FITZGERALD 
Dept.  of Medicine  and  Therapeutics 
lJni versity College 
~Joodview 
Stillorgan Road 
Dublin,  4 
treland 
Prof.  Or.  EigilL  F.  HVIOBERG 
Dept.  Clin.  Pharmacology 
University Hospital  (Rigshospitalet) 
9  Blegdamsvej 
DK-2100  Copenhagen  0 
Ctenmark 
Dr.  L.  OFFERHAUS 
Div.  of  Pharmacotherapy 
Central  Drug  Inspectorate 
Ministry of  Public  Health 
Environmental  Hygiene 
Dokter  Reijersstraat  10 
Leidschendam 
Netherlands 
Prof.  Dr.  J.  REUSE 
and 
Laboratoire de  Pharmacodynamie 
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